Search Results

Retrospective analysis of immune-related adverse events of the immune checkpoint inhibitors of PD-1/PD-l1 in the Fujian provincial hospital.

• Authors : Zheng, Jianping¹ (AUTHOR); Cui, Tongjian¹ (AUTHOR); Gao, Yu² (AUTHOR)

• Source: European Journal of Inflammation. 4/6/2022, p1-8. 8p.

Record details

Identification of Molecular Subtypes and Prognostic Features of Breast Cancer Based on TGF-β Signaling-related Genes.

• Authors : Qu, Jia¹ (AUTHOR); Wang, Mei-Huan¹ (AUTHOR); Gao, Yue-Hua¹ (AUTHOR)

• Source: Cancer Informatics. 2/3/2025, p1-14. 14p.

Record details

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker.

• Authors : Qureshi, Sadaf¹ (AUTHOR); Chan, Nancy^1,2 (AUTHOR); George, Mridula^1,2 (AUTHOR)

• Source: Biomarker Insights. 2/22/2022, Vol. 17, p1-11. 11p.

Record details

Efficacy of Shipixiaoji Granules, Lenvatinib, and Tislelizumab in Patients with Unresectable Hepatocellular Carcinoma: Protocol for a Prospective, Single-Arm, Phase Ⅱ Trial.

• Authors : Zhang, Zhen¹ (AUTHOR); Liang, Zicheng² (AUTHOR); Tan, Xiaoning¹ (AUTHOR)

• Source: Natural Product Communications. Dec2024, Vol. 19 Issue 12, p1-6. 6p.

Record details

Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.

• Authors : Federico Paly, Victoria; Kurt, Murat; Zhang, Lirong

Subjects: MELANOMA treatment; IMMUNE checkpoint inhibitors; NIVOLUMAB

• Source: MDM Policy & Practice. Jan-Jun2022, Vol. 7 Issue 1, p1-15. 15p.

Record details

Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.

• Authors : Al Nuhait, Mohammed^1,2 (AUTHOR) ; Bajnaid, Eshtyag³ (AUTHOR); Al Otaibi, Abdulmalik² (AUTHOR)

• Source: Science Progress. 3/10/2021, p1-14. 14p.

Record details

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors.

• Authors : Wu, Zhaozhen^1,2,3 (AUTHOR); Cui, Pengfei^1,4 (AUTHOR); Tao, Haitao¹ (AUTHOR)

• Source: Clinical Medicine Insights: Oncology. 2/25/2021, p1-10. 10p.

Record details

A Systematic Review of Clinical Practice Guidelines for Managing Pulmonary Toxicities Caused by Immune Checkpoint Inhibitors: Quality of Treatment Recommendations and Differences in Management Strategies Between Guidelines.

• Authors : Donkor, Kofi N¹ (AUTHOR) ; Jang, Hyeree¹ (AUTHOR); Sail, Reena² (AUTHOR)

• Source: Clinical Medicine Insights: Oncology. 11/8/2023, p1-22. 22p.

Record details

Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).

• Authors : Bersanelli, Melissa^1,2; Buti, Sebastiano¹; Cortellini, Alessio^3,4

• Source: Clinical Medicine Insights: Oncology. Jan-Dec2021, Vol. 15, p1-10. 10p.

Record details

Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges.

• Authors : Uchimiak, Katarzyna¹ (AUTHOR); Badowska-Kozakiewicz, Anna M.² (AUTHOR) ; Sobiborowicz-Sadowska, Aleksandra¹ (AUTHOR)

• Source: Clinical Medicine Insights: Oncology. 6/14/2022, p1-19. 19p.

Record details